肺表面活性物质联合布地奈德预防极低出生体重儿支气管肺发育不良的疗效观察

发布时间：2018-11-27 12:30

【摘要】：目的:研究分析布地奈德联合肺表面活性物质在预防极低出生体重儿支气管肺发育不良的临床疗效,为临床治疗提供参考。方法:采用前瞻性病例对照分析方法。选取2013年12月~2016年6月我院治疗的极低出生体重儿67例,以随机数字表法将其分为肺表面活性物质组(PS组)、布地奈德组和联合组,PS组给予气管插管内滴入肺表面活性物质,布地奈德组给予气管插管内滴入吸入用布地奈德混悬液,联合组给予联合使用上述药物。分别于治疗前、治疗后24h检测血气分析指标,计算氧合指数,并记录治疗期间并发症发生率。结果:用药前3组各项指标无显著差异(P0.05),治疗后24h时联合组血气分析指标及氧合指数均优于PS组和布地奈德组(P0.05)。3组治疗期间病死率及并发症发生率无显著差异(P0.05)。结论:布地奈德联合肺表面活性物质可有效预防极低出生体重儿支气管肺发育不良,具有较好的使用安全性。
[Abstract]:Objective: to study the clinical efficacy of budesonide combined with pulmonary surfactant in the prevention of bronchopulmonary dysplasia in very low birth weight infants. Methods: prospective case-control analysis was used. 67 cases of very low birth weight infants treated in our hospital from December 2013 to June 2016 were randomly divided into three groups: pulmonary surfactant group (PS group), budesonide group and combined group. The PS group received endotracheal intubation with pulmonary surfactant, the budesonide group with inhaled budesonide suspension and the combined group with the above drugs. Blood gas analysis indexes were measured before and 24 hours after treatment, oxygenation index was calculated, and the incidence of complications during treatment was recorded. Results: there was no significant difference between the three groups (P0.05). 24 hours after treatment, the blood gas analysis index and oxygenation index in the combined group were better than those in the PS group and budesonide group (P0.05). There was no significant difference in mortality and complication rate between the three groups (P0.05). Conclusion: budesonide combined with pulmonary surfactant can effectively prevent bronchopulmonary dysplasia in very low birth weight infants.
【作者单位】：洛阳市汝阳县人民医院;
【分类号】：R722.6

【相似文献】